JP2005500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500025A5
JP2005500025A5 JP2003500106A JP2003500106A JP2005500025A5 JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5 JP 2003500106 A JP2003500106 A JP 2003500106A JP 2003500106 A JP2003500106 A JP 2003500106A JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5
Authority
JP
Japan
Prior art keywords
sirna molecule
sequence
nucleotide
sirna
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500025A (ja
Filing date
Publication date
Priority claimed from US10/138,674 external-priority patent/US7034009B2/en
Application filed filed Critical
Priority claimed from PCT/US2002/017674 external-priority patent/WO2002096927A2/fr
Publication of JP2005500025A publication Critical patent/JP2005500025A/ja
Publication of JP2005500025A5 publication Critical patent/JP2005500025A5/ja
Pending legal-status Critical Current

Links

JP2003500106A 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節 Pending JP2005500025A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87016101A 2001-05-29 2001-05-29
US33446101P 2001-11-30 2001-11-30
US10/138,674 US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
PCT/US2002/017674 WO2002096927A2 (fr) 2001-05-29 2002-05-29 Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008149684A Division JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Publications (2)

Publication Number Publication Date
JP2005500025A JP2005500025A (ja) 2005-01-06
JP2005500025A5 true JP2005500025A5 (fr) 2005-09-15

Family

ID=27385212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003500106A Pending JP2005500025A (ja) 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Country Status (6)

Country Link
EP (1) EP1390385A4 (fr)
JP (2) JP2005500025A (fr)
AU (1) AU2002344237B8 (fr)
CA (1) CA2448320A1 (fr)
GB (1) GB0404461D0 (fr)
WO (1) WO2002096927A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002081628A2 (fr) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
WO2005078097A2 (fr) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Inhibition induite par l'interference arn de l'expression genetique, a l'aide d'un acide nucleique interferant court multifonctionnel (sina multifonctionnel)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2006203062B2 (en) * 2002-02-20 2009-03-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
MXPA04010282A (es) 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2006006948A2 (fr) 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
AU2004217526B2 (en) * 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
JP4762889B2 (ja) * 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
NZ574973A (en) * 2003-06-06 2010-10-29 Senesco Technologies Inc Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
KR20110007263A (ko) 2003-08-28 2011-01-21 노파르티스 아게 블런트-말단 및 3＇-변형체를 갖는 간섭 ｒｎａ 이중나선
EP1687410A4 (fr) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Oligonucleotides antisens optimises pour cibler le rein
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1711510A4 (fr) * 2004-02-05 2008-11-26 Intradigm Corp Therapeutique par des agents rnai appliquee dans le traitement de maladies oculaires resultant d'une neovascularisation
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1765336A4 (fr) * 2004-06-25 2010-03-10 Univ Johns Hopkins Inhibiteurs d'angiogenese
AU2005299672A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic RNAi agents for treating psoriasis
WO2006064519A2 (fr) * 2004-12-14 2006-06-22 National Institute Of Immunology Adnzymes destinees a l'inhibition de la replication du virus de l'encephalite japonaise
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR20080041145A (ko) 2005-04-12 2008-05-09 인트라디그엠 코오포레이션 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2007137981A1 (fr) * 2006-05-25 2007-12-06 Novartis Ag Inhibiteurs de tyrosine kinases
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
EP2432499A2 (fr) 2009-05-20 2012-03-28 Schering Corporation Modulation de récepteurs pilr pour traiter les infections microbiennes
DK2554173T3 (en) 2009-06-22 2017-01-16 Ampio Pharmaceuticals Inc PROCEDURE FOR DISEASE CARE
ES2655079T3 (es) 2009-09-10 2018-02-16 Merck Sharp & Dohme Corp. Uso de antagonistas de IL-33 para tratar enfermedades fibróticas
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
CN103068981A (zh) 2010-07-28 2013-04-24 爱尔康研究有限公司 靶向VEGFA的siRNA及用于体内治疗的方法
WO2012027206A1 (fr) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. Agents à base d'arni à un seul brin contenant une séquence intercalaire interne ne correspondant pas à un acide nucléique
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
EP3327125B1 (fr) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2013053076A1 (fr) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions et procédés pour le traitement de l'insuffisance cardiaque
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
WO2013142124A1 (fr) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Formes solides d'un promédicament nucléotidique thiophosphoramidate
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN105611955A (zh) * 2013-05-22 2016-05-25 上海泽生科技开发有限公司 缓释纽兰格林治疗心力衰竭
CN103627709A (zh) * 2013-12-06 2014-03-12 孙仑泉 抑制血管内皮生长因子受体基因表达的脱氧核酶
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU8525098A (en) * 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
WO2003070910A2 (fr) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition induite par interference d'arn du facteur de croissance endothelial vasculaire et expression genetique du recepteur de facteur de croissance endothelial vasculaire au moyen d'acides nucleiques interferents courts (sina)

Similar Documents

Publication Publication Date Title
JP2005500025A5 (fr)
McKenzie et al. Recent progress in non-native nucleic acid modifications
JP2005517452A5 (fr)
JP2005524393A5 (fr)
JP2005517427A5 (fr)
JP2005517432A5 (fr)
JP2005517436A5 (fr)
EP1097939B1 (fr) Méthode pour la synthèse d'isoguanosine et de ses 2'-derivés
JP2006502694A5 (fr)
Giannaris et al. Oligoribonucleotides containing 2′, 5′-phosphodiester linkages exhibit binding selectivity for 3′, 5′-RNA over 3′, 5′-ssDNA
JP2005518803A5 (fr)
JP2003505108A (ja) 転写フリーｓｅｌｅｘ
JP2008283975A5 (fr)
JP2003511016A (ja) オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
JP2005517438A5 (fr)
JP2007529224A5 (fr)
JP2010533499A5 (fr)
NZ599237A (en) Sirna compounds comprising terminal substitutions
CA2457528A1 (fr) Inhibition a mediation par interference arn de l'expression du gene du virus de l'hepatite c (vhc) au moyen d'acide nucleique interferent court (sina)
JP2009514877A5 (fr)
JP2002531053A5 (fr)
JP7033591B2 (ja) 治療用オリゴヌクレオチドの捕捉および検出
JP2009502138A5 (fr)
Hunziker et al. Nucleic acid analogues: synthesis and properties
Suparpprom et al. Perspectives on conformationally constrained peptide nucleic acid (PNA): insights into the structural design, properties and applications